

CURRICULUM VITAE



PD Dr. med. Oliver Riesterer

Klinik und Poliklinik für Radioonkologie
Universitätsspital Zürich
Rämistr. 100
CH-8091 Zürich

044-2553748 (Phone)
044-2554547(Fax)
oliver.riesterer@usz.ch
www.radio-onkologie.usz.ch

GENERAL INFORMATION

Social Status	Married, 3 children
Citizenship	Switzerland (Bürgerort: Wichtrach BE) and Germany
Home address	Kurfürstenstrasse 69, 8002 Zürich
Private phone	+41433775655, Mobil: +41789167071
Private email	oliver.riesterer@yahoo.com

EDUCATION

1980-1988	Hohenstaufen Gymnasium Göppingen
1990-1992	Undergraduate student, University of Ulm, Germany
1993-1997	Graduate student University of Cologne, Germany

UNIVERSITY DEGREES

1997	Medical Degree
1998	Doctoral Degree: Prof. Dr. Klaus Lackner, Department of Radiology, University of Cologne, Germany: «Results of Transarterial Chemoembolisation of Liver Tumors»
2012	Habilitation: Prof. Dr. Urs Martin Lütolf, Department of Radiation Oncology, University of Zurich: «Inhibition of Tumor Angiogenesis and Ionizing Radiation-From Bench to Bedside»

ACADEMIC APPOINTMENTS

2007	Board Certification Swiss Society for Radiation Oncology
2006-2008	UICC American Cancer Society Fellowship, Department of Experimental Radiation Oncology MD Anderson Cancer Center, Houston, Texas.

INSTITUTIONAL APPOINTMENTS

2008-2013	Oberarzt (Consultant), Department of Radiation Oncology, University Hospital Zurich
2013-2018	Leitender Arzt (Senior Consultant), Department of Radiation Oncology, University Hospital Zurich
01.06.18-31.12.18	Leitender Arzt (Senior Consultant), Center for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau
01.01.19-present	Research Associate at the Department of Radiation Oncology, University Hospital Zurich
01.01.19-present	Head of Radiation Oncology Cantonal Hospital Aarau, Deputy Chairman of the Radiation Oncology Center KSA-KSB

PROFESSIONAL APPOINTMENTS

1997-1999	Resident in Internal Medicine, Kantonsspital Baden, Switzerland
1999-2000	Resident in Radiation Oncology, University Hospital Zurich, Switzerland

2000-2003 Research Fellowship, Laboratory for Molecular Radiobiology, University Hospital Zurich
2004-2006 Resident in Radiation Oncology University Hospital Zurich, Switzerland

EDUCATION IN HEALTH MANAGEMENT

1997-1999 Zertifikatskurs (CAS): St.Galler Seminar für systemisch-integratives Management im Gesundheitswesen (6 Modules, 22 days)
2012-2013 USZ seminars: Leadership I and II (8 days), Health Economy (1day), Health Ethics (1day)

GRANTS

2020 EU Horizon Grant Hyperboost: Creation of advanced cancer treatment planning to boost the effect of Radiotherapy by combining with hyperthermia, heating the tumor. Total grant sum 3,7 Mio Euro. Co-Investigator 281'000.- Euro
2017 SNF R'Equip: MIG-ART – MRI gestützte adaptive Radio-Onkologie. Projektpartner. Grant Sum 1'000'000.- sfr.
2015 Tumor oxygenation measured quantitatively and non-invasively by near-infrared optical tomography. Swiss cancer research. Co-applicant 167 450.-sfr.
2014 Combined kidney and hematopoietic cell transplantation to cure end-stage renal disease" (swisstolerance.ch). Co-Applicant. Horten Foundation. Grant sum 215'000.-sfr.
2014 SNF Grant "Development of prediction models for liver, lung and breast tumors and implementation and verification of prediction filters for advanced couch tracking in a clinical environment. Co Applicant. Grant Sum 581'316.-sfr.
2013 Merck: Merck KGaA and Threshold Pharmaceuticals Research Grant: "Pre-clinical study of TH-302 combined with Ionizing Radiation in vitro and in vivo. 140'000.- Euro (Primary Applicant together with M. Pruschy)
2012 KFSP (Klinischer Forschungsschwerpunkt): "Tumor Oxygenation" (Large Interdisciplinary Research Grant from the University of Zurich). Team leader clinical radiation oncology part. Director PD Dr. Martin Wolf, Biomedical Optics Research Laboratory, USZ, Division of Neonatology, USZ. 290'000.- sfr. (Total Grant Sum 3'500 000.- sfr.)
2012 Swiss National Fund: "Targeting of Ionizing Radiation–Activated Treatment Resistances: Radiation-Induced Paracrine and Autocrine Factors". Co-applicant. Main-applicant: Prof. Pruschy. Grant Sum: 390'000.-sfr.
2011 Swiss Cancer League: Targeting of ionizing radiation-activated treatment resistances: radiation-induced para- and autocrine factors. Co-applicant. Main- applicant Prof. Dr. sc. Nat. Martin Pruschy) Grant Sum: 320'000.-sfr.
2010 Matching Fund of the University Zurich 2010 and Supplementary Matching Fund 2011: "A randomized phase II study in patients with advanced head and neck cancer of standard chemoradiation and add-on concurrent cetuximab ± consolidation cetuximab". Main-applicant. Total Grant Sum 225'000.-sfr.
2010 Merck Research Grant: A randomized phase II study in patients with advanced head and neck cancer of standard chemoradiation and add-on concurrent cetuximab ± consolidation cetuximab. Main applicant. Grant Sum 450'000.-sfr.
2006 Improvement of Radiotherapy by Molecular Targeting Approaches: Focus on Cancer Cell Clonogens (CCCs). 2006-2008. American Cancer Society UICC International Fellowship for Beginning Investigators (ACSBI) and Research Fellowship and Nachwuchs-foerderungskommission University of Zurich: Main-applicant: Total grant sum: 196'593.-sfr

TEACHING EXPERIENCE

Seit 2008 Praktikum und Tutorat in Radio-Onkologie und Onkologie
Seit 2008 Gastro-chirurg.-onkolog. Fallvorstellung
Seit 2011 Seminar "Klinische Studien und Forschung in der Radio-Onkologie"
2005-2006 Seminar "Clinical research and molecular biology" (4.Studienjahr)
2015-2018 Pathophysiologie und Klinik Blut-Onkologie

2015-2018

Schwerpunktprogramm «Medizin und Technik» (ETH und UZH)

AWARDS

- Laufbahnförderungsprogramm der Universität Zürich seit 2012
- AACR Recognition for “Highly Rated Poster Presentation” (poster scored in the top 3-4% of all poster presentations) at 100th annual meeting of AACR. Colorado, USA, 2009
- Best Oral Presentation Award, Annual Meeting of SASRO (Scientific Association of Swiss Radiation Oncology, Baden Switzerland 2009
- UICC/American Cancer Society Fellowship 2006
- Young Researcher’s Award, 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology, Lucerne, Switzerland, 2004
- Best Poster Award at the Wolfsberg Meeting for Radiation Biology/Oncology, Wolfsberg, Switzerland, 2003
- Best Poster Award at the International Wolfsberg Meeting for Radiation Biology/Oncology, Wolfsberg, Switzerland, 2002

PEER REVIEWER

International Journal of Radiation Oncology Biology Physics
Radiotherapy and Oncology
Molecular Cancer Research
Journal of Hepatology
Radiation Oncology
BMC Cancer
Acta Oncologica
Treatment Cancer Reviews
Swiss Cancer League

MEMBERSHIPS

SRO (Swiss Society of Radiation Oncology)
ESTRO (European Society of Radiation Oncology)
ASTRO (American Society for Therapeutic Radiology and Oncology)
SASRO (Swiss Society of Scientific radiation Oncology)
FMH (Medical Society of Switzerland)

PRINCIPAL / CO-INVESTIGATOR IN CLINICAL STUDIES

- EORTC22055: Phase III study comparing post-operative conformal radiotherapy to no post-operative conformal radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal involvement, Local principal investigator and principle investigator in the frame of SAKK for Switzerland
- Javelin Head and Neck 100: A randomized double-blind phase 3 study of Avelumab in combination with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) versus standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck. Local PI and PI for Switzerland.
- Intergroup Study (EORTC-1219-ROG-HNCG/DAHANCA-29). A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck. Local PI
- EORTC 22113-08113. LungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomized phase III trial. RT Plan Reviewer on behalf of EORTC (QA Team)
- Functional Imaging by means of H₂O/O₂-PET/CT or functional MRI for determination of tumor hypoxia before, during and after radiotherapy in patients with head and neck cancer, *Principal Investigator*
- Validation of BOLD MRI against H₂O/O₂-PET/CT for determination of tumor oxygenation in patients with brain tumors, *Co-Investigator*
- Tumor secretome before, during and after radiotherapy in patients with lung cancer. Principal Investigator.
- Correlation between retrospective data parameters and prospectively determined tissue hypoxia biomarkers in corresponding tumor samples of head and neck cancer patients, *Co-Investigator*
- A phase II, randomized, open-label, single center study in patients with advanced head and neck cancer to investigate efficacy and safety of standard chemoradiation and add-on concurrent cetuximab ± consolidation cetuximab, *Principal Investigator*

- Protocol SAKK 17/04. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial, *Radiation Oncology Study Chair*

Zurich, 12.07.2020

Oliver Riesterer

PUBLICATIONS

LINK TO PEER-REVIEWED PUBLICATIONS:

[HTTPS://PUBMED.NCBI.NLM.NIH.GOV/?TERM=Riesterer+O&SORT=DATE](https://pubmed.ncbi.nlm.nih.gov/?term=Riesterer+O&sort=date)

SCIENTIFIC PUBLICATIONS

Total	94
Original articles	66
Review articles	24
Editorials	1
Monographies	1
Case Reports	2

INVITED TALKS / CONCERENCE CONTRIBUTIONS

Total	111
Oral	75
Posters	39

JOURNAL ARTICLES (PEER REVIEWED)

1. **Riesterer O**, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. *Radiother Oncol*. 2020 Jun
2. Rogers S, Eberle B, Vogt DR, Meier E, Moser L, Gomez Ordoñez S, Desborough S, **Riesterer O**, Takacs I, Hasler P, Bodis S. Prospective Evaluation of Changes in Pain Levels, Quality of Life and Functionality After Low Dose Radiotherapy for Epicondylitis, Plantar Fasciitis, and Finger Osteoarthritis. *Front Med (Lausanne)*. 2020 May 19;7:195.
3. Bogowicz M, Jochems A, Deist TM, Tanadini-Lang S, Huang SH, Chan B, Waldron JN, Bratman S, O'Sullivan B, **Riesterer O**, Studer G, Unkelbach J, Barakat S, Brakenhoff RH, Nauta I, Gazzani SE, Calareso G, Scheckenbach K, Hoebbers F, Wesseling FWR, Keek S, Sanduleanu S, Leijenaar RTH, Vergeer MR, Leemans CR, Terhaard CHJ, van den Brekel MWM, Hamming-Vrieze O, van der Heijden MA, Elhalawani HM, Fuller CD, Guckenberger M, Lambin P. Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. *Sci Rep*. 2020 Mar 11;10(1)
4. de Galiza Barbosa F, **Riesterer O**, Tanadini-Lang S, Stieb S, Studer G, Pruschy M, Huber GF, Huellner MW, Stolzmann P, Veit-Haibach P. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. *Head Neck*. 2020 Feb;42(2):163-170.
5. Bogowicz M, Tanadini-Lang S, Guckenberger M, **Riesterer O**. Combined CT radiomics of primary tumor and metastatic lymph nodes improves prediction of loco-regional control in head and neck cancer. *Sci Rep*. 2019 Oct 23;9(1):15198.
6. Elicin O, Ermiş E, Oehler C, Aebersold DM, Caparrotti F, Zimmermann F, Studer G, Henke G, Adam L, Anschuetz L, Ozsahin M, Guckenberger M, Shelan M, Kaydihan N, **Riesterer O**, Prestwich RJD, Spielmann T, Giger R, Şen M. Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study. *Front Oncol*. 2019 Sep 20;9:932.
7. Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, **Riesterer O**, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. *Liver Cancer*. 2019 Jul;8(4):281-294.
8. Bogowicz M, Tanadini-Lang S, Veit-Haibach P, Pruschy M, Bender S, Sharma A, Hüllner M, Studer G, Stieb S, Hemmatazad H, Glatz S, Guckenberger M, **Riesterer O**. Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma. *Acta Oncol*. 2019 Oct;58(10):1514-1518.
9. **Riesterer O**, Ciernik IF, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Kraysenbuehl J; Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Swiss Group for Clinical Cancer Research (SAKK). *Radiother Oncol*. 2019 Sep;138:121-125

10. Pouymayou B, Balermipas P, **Riesterer O**, Guckenberger M, Unkelbach J. A Bayesian network model of lymphatic tumor progression for personalized elective CTV definition in head and neck cancers. *Phys Med Biol.* 2019 Aug 14;64(16):165003. doi: 10.1088/1361-6560/ab2a18
11. Stieb S, **Riesterer O**, Boss A, Weiss T, Guckenberger M, Özbay PS, Nanz D, Rossi C. Dependency of the blood oxygen level dependent-response to hyperoxic challenges on the order of gas administration in intracranial malignancies. *Neuroradiology.* 2019 Jul;61(7):783-793.
12. Brunner TB, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, **Riesterer O**, Duma MN, Wachter S, Baus W, Gerum S, Guckenberger M, Gkika E. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. *Radiother Oncol.* 2019 Mar;132:42-47. doi: 10.1016/j.radonc.2018.11.015. Epub 2018 Dec 20.
13. Helfenstein S, **Riesterer O**, Meier UR, Papachristofilou A, Kasenda B, Pless M, Rothschild SI. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. *Radiat Oncol.* 2019 Feb 11;14(1):32. doi: 10.1186/s13014-019-1235-y.
14. Jöhl A, Bogowicz M, Ehrbar S, Guckenberger M, Klöck S, Meboldt M, **Riesterer O**, Zeilinger M, Schmid Daners M, Tanadini-Lang S. Body motion during dynamic couch tracking with healthy volunteers. *Phys Med Biol.* 2018 Dec 19;64(1):015001. doi: 10.1088/1361-6560/aaf361.
15. Stieb S, Malla M, Graydon S, **Riesterer O**, Klöck S, Studer G, Tanadini-Lang S. Dosimetric influence of pitch in patient positioning for radiotherapy of long treatment volumes; the usefulness of six degree of freedom couch. *Br J Radiol.* 2018 Nov;91(1091):20170704. doi: 10.1259/bjr.20170704. Epub 2018 Jul 25
16. Pavic M, Bogowicz M, Würms X, Glatz S, Finazzi T, **Riesterer O**, Roesch J, Rudofsky L, Friess M, Veit-Haibach P, Huellner M, Opitz I, Weder W, Frauenfelder T, Guckenberger M, Tanadini-Lang S. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. *Acta Oncol.* 2018 Mar 7:1-5. doi: 10.1080/0284186X.2018.1445283. [Epub ahead of print]
17. Leijenaar RT, Bogowicz M, Jochems A, Hoebbers FJ, Wesseling FW, Huang SH, Chan B, Waldron JN, O'Sullivan B, Rietveld D, Leemans CR, Brakenhoff RH, **Riesterer O**, Tanadini-Lang S, Guckenberger M, Ikenberg K, Lambin P. Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. *Br J Radiol.* 2018 Mar 22:20170498. doi: 10.1259/bjr.20170498. [Epub ahead of print].
18. Tanadini-Lang S, Bogowicz M, Veit-Haibach P, Hüllner M, Pauli C, Shukla V, Guckenberger M, **Riesterer O**. Exploratory radiomics in computed tomography perfusion of prostate cancer. *Anticancer Res.* 2018 Feb;38(2):685-690
19. Özbay PS, Stieb S, Rossi C, **Riesterer O**, Boss A, Weiss T, Kuhn F, Pruessmann KP, Nanz D. Lesion magnetic susceptibility response to hyperoxic challenge: A biomarker for malignant brain tumor microenvironment? *Magn Reson Imaging.* 2017 Dec 5. doi: 10.1016/j.mri.2017.12.004. [Epub ahead of print]
20. Jöhl A, Bogowicz M, Ehrbar S, Guckenberger M, Klöck S, Meboldt M, **Riesterer O**, Zeilinger M, Schmid Daners M, Tanadini-Lang S. Unconscious physiological response of healthy volunteers to dynamic respiration-synchronized couch motion. *Radiat Oncol.* 2017 Nov 28;12(1):189
21. Datta NR, Pestalozzi B, Clavien PA, Siebenhüner A, Puric E, Khan S, Mamot C, **Riesterer O**, Knuchel J, Reiner CS, Bodis S; members of the HEATPAC Trial Group. "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. *Radiat Oncol.* 2017 Nov 21;12(1):183
22. Bogowicz M, Leijenaar RTH, Tanadini-Lang S, **Riesterer O**, Pruschy M, Studer G, Unkelbach J, Guckenberger M, Konukoglu E, Lambin P. Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models. *Radiother Oncol.* 2017 Dec;125(3):385-391 IF 4.328
23. Karava K, Ehrbar S, **Riesterer O**, Roesch J, Glatz S, Klöck S, Guckenberger M, Tanadini-Lang S. Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer. *Radiat Oncol.* 2017 Nov 9;12(1):175
24. Habraken SJM, Sharfo AWM, Buijssen J, Verbakel WFAR, Haasbeek CJA, Öllers MC, Westerveld H, van Wieringen N, Reerink O, Seravalli E, Braam PM, Wendling M, Lacornerie T, Mirabel X, Weytjens R, Depuydt L, Tanadini-Lang S, **Riesterer O**, Haustermans K, Depuydt T, Dwarkasing RS, Willemsen FEJA, Heijmen BJM, Méndez Romero A. The TRENDY multicenter randomized trial on hepatocellular carcinoma - Trial QA including automated treatment planning and benchmark-case results. *Radiother Oncol.* 2017 Dec;125(3):507-513
25. Ehrbar S, Schmid S, Jöhl A, Klöck S, Guckenberger M, **Riesterer O**, Tanadini-Lang S. Comparison of multi-leaf collimator tracking and treatment-couch tracking during stereotactic body radiation therapy of prostate cancer. *Radiother Oncol.* 2017 Dec;125(3):445-452
26. Panje C, **Riesterer O**, Glanzmann C, Studer G. Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer. *BMC Cancer.* 2017 Sep 11;17(1):643
27. Bogowicz M, **Riesterer O**, Ikenberg K, Stieb S, Moch H, Studer G, Guckenberger M, Tanadini-Lang S. Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. *IJROBP.* 2017 Nov 15;99(4):921-928

28. Bogowicz M, **Riesterer O**, Stark LS, Studer G, Unkelbach J, Guckenberger M, Tanadini-Lang S. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. *Acta Oncol.* 2017 Nov;56(11):1531-1536
29. Streller T, Rusch U, Herraiz Lablanca MD, Minneken I, Najafi Y, Shrestha B, Oertel S, **Riesterer O**. The effect of endorectal balloon on anorectal dose during postoperative volumetric arc radiotherapy of prostate cancer. *Radiother Oncol.* 2017 Jun;123(3):454-458
30. Nytko KJ, Grgic I, Bender S, Ott J, Guckenberger M, **Riesterer O**, Pruschy M. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. *Radiother Oncol.* 2017 Jun;123(3):454-458
31. Nesteruk M, Riesterer O, Bundschuh R, Veit-Haibach P, Huellner M, Studer G, Stieb S, Glatz S, Pruschy M, Guckenberger M, Tanadini-Lang S. SU-F-R-51: Radiomics in CT Perfusion Maps of Head and Neck Cancer. *Med Phys.* 2016 Jun;43(6):3384-3385.
32. Bogowicz M, **Riesterer O**, Bundschuh RA, Veit-Haibach P, Hüllner M, Studer G, Stieb S, Glatz S, Pruschy M, Guckenberger M, Tanadini-Lang S. Stability of radiomic features in CT perfusion maps. *Med Phys.* 2016 Jun;43(6):3384-3385.
33. Ernst J, Ikenberg K, Apel B, Schumann DM, Huber G, Studer G, Rordorf T, **Riesterer O**, Rössle M, Korol D, Bredell MG. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. *Oncotarget.* 2016 Nov 15;7(46):76151-76158
34. Stieb S, Boss A, Wurnig MC, Özbay PS, Weiss T, Guckenberger M, **Riesterer O**, Rossi C2. Non-parametric intravoxel incoherent motion analysis in patients with intracranial lesions: Test-retest reliability and correlation with arterial spin labeling. *Neuroimage Clin.* 2016 Jun 2;11:780-8.
35. Sharma A, Bender S, Zimmermann M, **Riesterer O**, Broggin-Tenzer A, Pruschy M. Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer. *Cancer Res.* 2016 Sep 1;22(17):4428-39
36. **Riesterer O**, Weder W and Stahel R. Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply. *Lancet Oncol.* 2016 Feb;17(2):e44-5
37. Stahel RA, **Riesterer O**, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Kraysenbuehl J, Ribi K, Ciernik LF, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol.* 2015 Dec;16(16):1651-8
38. Nesteruk M, Lang S, Veit-Haibach P, Studer G, Stieb S, Glatz S, Hemmatazad H, Ikenberg K, Huber G, Pruschy M, Guckenberger M, Klöck S, **Riesterer O**. Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDG uptake in head and neck squamous cell carcinoma. *Radiother Oncol.* 2015 Oct;117(1):125-31.
39. Ehrbar S, Lang S, Stieb S, **Riesterer O**, Stark LS, Guckenberger M, Klöck S. Three-dimensional versus four-dimensional dose calculation for volumetric modulated arc therapy of hypofractionated treatments. *Z Med Phys.* 2016 Mar;26(1):45-53.
40. Stieb S, Lang S, Linsenmeier C, Graydon S and **Riesterer O**. Safety of High-Dose-Rate Stereotactic Body Radiotherapy. *Radiat Oncol.* 2015 Jan 23;10(1):27
41. Hrbacek J, Lang S, Graydon S, Klöck S, **Riesterer O**. Comparison of flattened and unflattened beams for stereotactic ablative radiotherapy of stage I non-small cell lung cancer. *Med Phys.* 2014 Mar;41(3):031709
42. Janssen S, Glanzmann C, Bauerfeind P, Stieb S, Studer G, Brown M, **Riesterer O**. Clinical experience of SIB-IMRT in anal cancer and selective literature review. *Radiat Oncol.* 2014 Sep 8;9:199
43. Lang S, Zeimet J, Ochsner G, Schmid Daners M, **Riesterer O**, Klöck S: Development and evaluation of a prototype tracking system using the treatment couch. *Med. Phys.* 2014 Feb; 41, 021720
44. Kraysenbuehl J, Dimmerling P, Ciernik F, **Riesterer O**. Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant mesothelioma. *Radiat Oncol.* 2014 Jan 24;9:32
45. Studer G, Linsenmeier C, **Riesterer O**, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. *Radiat Oncol.* 2013 Nov 5;8(1):259
46. Kraysenbühl J, **Riesterer O**, Graydon SN, Dimmerling P, Klöck S, Ciernik F. Intensity Modulated Radiotherapy and volumetric arc radiotherapy for malignant pleural mesothelioma after extrapleural pneumonectomy. *J Appl Clin Med Phys.* 2013 Jul 8;14(4):4130.
47. Stephanie L, Shrestha B, Graydon SN, Cavelaars F, Linsenmeier C, Klöck S, Studer G, **Riesterer O**. Clinical application of flattening filter free beams for extracranial stereotactic radiotherapy. *Radiother Oncol.* 2013 Feb;106(2):255-9
48. Chen SA, Hiley C, Nickleach D, Petsuksiri J, Andic F, **Riesterer O**, Switchenko JM, Torres MA. Breast reconstruction and post-mastectomy radiation practice. *Radiat Oncol.* 2013 Mar 2;8:45
49. Raju U, **Riesterer O**, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. *Radiother Oncol* 2012 Nov;105(2):241-9
50. Studer G, Brown ML, Bredell M., Graetz KW, Huber G, Linsenmeier C, Najafi Y, **Riesterer O**, Rordorf T, Schmid S, Glanzmann G. Follow-up after IMRT in oral cavity cancer: update. *Radiother Oncol* 2012, June 11, 7:84

51. Torres MA, Raju U, Molkenkine D, **Riesterer O**, Milas L, Ang KK. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. *Invest New Drugs*. 2011 Aug; 29(4):554-61.
52. **Riesterer O**, Oehler-Jänne C, Jochum W, Broggin-Tenzer A, Vuong V, Pruschy M. Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study. *Radiat Oncol*. 2011 Jun 8;6: 66.
53. **Riesterer O**, Matsumoto F, Wang L, Pickett J, Molkenkine D, Giri U, Milas L, Raju U. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. *Invest New Drugs*. 2011 Jun;29(3):514-22. Paper listed in Daily Updates.
54. **Riesterer O**, Yang Q, Raju U, Torres M, Molkenkine D, Patel N, Valdecanas D, Milas L, Ang KK. Combination of Anti-IGF-1R Antibody A12 and Ionizing Radiation in Upper Respiratory Tract Cancers. *Int J Radiat Oncol Biol Phys*. 2011 Mar 15;79(4):1179-87.
55. Koto M, Cho H, **Riesterer O**, Giri U, Story MD, Ha CS and Raju U. Human Lymphoma Cells Develop Resistance to Radiation in the Presence of Astrocytes In Vitro. *Anticancer Res*. 2011 Jan, 31(1):33-8
56. Skvortsova I, Skvortsov S, Raju U, Stasyk T, **Riesterer O**, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. *Radiother Oncol*. 2010 Jul, 96(1):108-15
57. Cho H, Koto M, **Riesterer O**, Molkenkine DP, Giri U, Milas L, Story MD, Ha CS, Raju U. Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study. *Anticancer Res*. 2009 Nov, 29(11):4409-15.
58. **Riesterer O**, Mason KA, Raju U, Yang Q, Hittelman W, Ang KK and Milas L. Enhanced Response of A431 Tumors in Irradiated Tumor Bed to C225. *Radiother Oncol*. 2009 Sep, 92(3):383-7.
59. **Riesterer O**, Hlushchuk R, Baum O, Wood J, Gruber G, Pruschy M and Djonov V. Vascular normalization by intussusceptive angiogenesis after antiangiogenic therapy and ionizing radiation. (shared first authorship). *Am J Pathol*. 2008 173(4):1173-85.
60. Oehler C, **Riesterer O**, Jochum W, Broggin A and Pruschy M. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibitor NVP-AEE788 enhances tumor growth inhibition by ionizing. *Mol Cancer Ther*. 2007 6(9):2496-504.
61. Cerciello F, **Riesterer O**, Sherweif M., Odermatt B and Ciernik I F. Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? *Gynecol Oncol*. 2007 106(2):394-9.
62. **Riesterer O**, Honer M, Jochum W, Oehler C, Ametamey S and Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by anti-angiogenic treatment. *Clin Cancer Res*. 2006, 12(11):3518-3524. (shared first authorship)
63. **Riesterer O**, Zingg D, Glanzmann C, Bodis S and Pruschy M. Differential Activation of the Phosphatidylinositol 3'-Kinase/Akt-Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells. (shared first authorship). *Cancer Res*. 2004, 64:5398-5406.
64. **Riesterer O**, Tenzer A, Zingg D, Hofstetter B, Vuong V, Pruschy M, and Bodis S. Novel radiosensitizers for locally advanced epithelial tumours: Inhibition of the PI3K/Akt survival pathway in tumour cells and in tumour associated endothelial cells as a novel target? *Int J Radiat Oncol Biol Phys*. 2004, 58(2):361-8.
65. **Riesterer O**, Hummerjohann J, Bodis S, and Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF-Receptor and the mTor pathway in endothelial cells. *Oncogene*. 2004, 23(26):4624-35.
66. Hess C, Vuong V, Hegyi I, **Riesterer O**, Wood J, Fabbro D, Glanzmann C, Bodis S and Pruschy M. Effects of combination therapy with the VEGF receptor tyrosine kinase PTK/ZK222584 and ionizing radiation on endothelial cell proliferation and tumor growth control. *British J Cancer*. 2001, 85(12):2010-2016.

REVIEWS

1. **Riesterer O**. Stellenwert der Radiochemotherapie bei Pankreas und hepatobiliären Karzinomen. *Schweizer Krebsbulletin*. 01, März 2020
2. Tanadini-Lang S, Balermipas P, Guckenberger M, Pavic M, **Riesterer O**, Vuong D, Bogowicz M. Radiomic biomarkers for head and neck squamous cell carcinoma. *Strahlenther Onkol*. 2020 Jun 3. doi: 10.1007/s00066-020-01638-4. Online ahead of print.
3. Stieb S, Eleftheriou A, Warnock G, Guckenberger M, **Riesterer O**. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. *Eur J Nucl Med Mol Imaging*. 2018 Nov;45(12):2201-2217. doi: 10.1007/s00259-018-4116-y. Epub 2018 Aug 20
4. **Riesterer O**. Radiochemotherapie von Kopf-Hals Tumoren: Strategie der De-Eskalation und Eskalation abhängig vom HPV Status. 07_2017 info@onkologie
5. Pruschy M und **Riesterer O**. Lässt sich die Wirksamkeit der Radiotherapie mit Medikamenten erhöhen? *InFo ONKOLOGIE & HÄMATOLOGIE* 2016; Vol. 4, Nr. 7–8
6. Theile G, Riesterer O, Andratschke N, Guckenberger M. Radiotherapie: Herausforderungen und Möglichkeiten bei älteren Patienten. *InFo ONKOLOGIE & HÄMATOLOGIE* 2016; Vol. 4, Nr. 7–8

7. Rudofsky L, Garcia Schüler H, Guckenberger M, Riesterer O. Multimodale Therapie des Rektumkarzinoms. Müssen alle Patienten operiert werden? 03 _ 2016 info@onkologie
8. Roesch J, Guckenberger M, **Riesterer O**. Individualisierte Therapie des malignen Pleuramesothelioms. Schweizer Zeitschrift für Onkologie 4/2015
9. Guckenberger M, **Riesterer O**, Theile G, Andratschke N. Herausforderungen und Chancen in der radioonkologischen Behandlung von Patienten im Alter. Schweizer Krebsbulletin. September 2015.
10. Guckenberger M, **Riesterer O**, Andratschke N. Extrakranielle Stereotaxie von Leber- und Pankreas Tumoren. Invited Review. 01 _ 2015 info@onkologie
11. **Riesterer O** und Guckenberger M: Stereotaktische Strahlentherapie von Metastasen: Palliativer Effekt und Tumorkontrolle. Invited Review. Der Onkologe. 2014.
12. **Riesterer O**: SAMO Interdisciplinary Workshop on Chest Tumors: Extrakranielle Stereotaktische Radiotherapie. Leading Opinions Hämatologie und Onkologie 2/14: 168
13. Lang S and **Riesterer O**. Modern Techniques in Radiation Oncology. Invited Artikel. Swiss Physical Society SPG Mitteilungen, Ausgabe 41, November 2013
14. **Riesterer O**. Extrakranielle stereotaktische Radiotherapie bei frühen nichtkleinzelligen Bronchialkarzinomen und Oligometastasen. Invited Review. Praxis (Bern 1994). 2013 Oct 16;102(21)
15. **Riesterer O**. Präoperative Radiochemotherapie beim Ösophaguskarzinom. Invited Review. Info@Onkologie Vol.3_Ausgabe 03_Juli 2013.
16. **Riesterer O**. Angiogenese Inhibitoren und Radiotherapie. Invited review. Praxis 2012 Aug 8;101(16):1031-7.
17. Kati Emrah, **Riesterer O**. Hepatobiliäre Karzinome. Neue Möglichkeiten der Radiotherapie. Invited Review. Info@Onkologie 2012, Vol.2, 4-August.
18. **Riesterer O**. Kombinierte Angiogenese-/Vaskulogenese-Inhibition und Radiotherapie. Invited Review. Leading Opinions Hämatologie und Onkologie 31 2011: 46-49.
19. Samaras P, Geier A, **Riesterer O**, Dutkowski P. Tumore des biliären Trakts. Schweizer Zeitschrift für Onkologie 2/2011.
20. Dindo O, **Riesterer O**, Weber A and Hahnloser D. Humanes Papillomavirus und Analkarzinom. Gastroenterologe. 2010, 5:318-325.
21. **Riesterer O**, Milas L, and Ang K. Targeted Therapies in Head and Neck Cancer. J Surg Oncol. 2008 Jun 15, 97(8):708-11.
22. **Riesterer O**, Milas L and Ang K. The Use of Molecular Biomarkers for Predicting the Response to Radiotherapy with or without Chemotherapy. J Clin Oncol. 2007, 25(26):4075-83.
23. Oehler C, Dickinson DJ, Broggin-Tenzer A, Hofstetter B, Hollenstein A, **Riesterer O**, Vuong V and Pruschy M. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr Pharm Des. 2007, 13(5):519-35.
24. Tenzer A, Zingg D, **Riesterer O**, Vuong V, Bodis S and Pruschy M. Signal Transduction Inhibitors as Radiosensitizers. Curr. Med. Chem.-Anti-Cancer Agents. 2002, 2:727-742.

EDITORIALS

1. **Riesterer O**. InFo ONKOLOGIE & HÄMATOLOGIE 2016; Vol. 4, Nr. 7-8

CASE REPORTS

1. Britschgi C, **Riesterer O**, Burger IA, Guckenberger M, Curioni-Fontecedro A. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiat Oncol. 2018 May 31;13(1):102.
2. Stieb, S, **Riesterer O**, Brüssow C, Pestalozzi B, Guckenberger M, Weiler S. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature. Strahlenther Onkol. 2016 Feb 23. [Epub ahead of print
3. **Riesterer O**, Gmuer J, Lütolf U. Repeated and Preemptive Palliative Radiotherapy of Symptomatic Hepatomegaly in a Patient with Advanced Myelofibrosis. Onkologie. 2008 Jun, 31(6):325-7

BOOK CHAPTERS

1. **Riesterer O**, Pruschy M, Bodis S: Role of Signal Transduction Modification. In Medical Radiology. Volume: Biological Modification of Radiation Response (edited by C: Nieder, L. Milas, K.K. Ang). Springer Verlag, Germany, 2003-05-27